PreLeish: Predicting Visceral Leishmaniasis in HIV Infected Patients

Principal investigator

Location

Ethiopia
Topics

HIV/AIDS, Leishmaniasis
Methodology

Observational study
Reference

OCA016-08
Views

683
Downloaded

4

Purpose of study

To study the asymptomatic period preceding the onset of active Visceral Leishmaniasis (VL) in HIV‐infected individuals from VL endemic regions in Ethiopia as an avenue to develop an evidence‐based screen and treat strategy to prevent progression t...

Study status

Concept
Protocol & ERB
Implementation
Completion
Archived

Study timeline

Documents

Study_concept_paper_PreLeisH.docx 26.7 KB
1_160603_PreLeisH_CoverLetter_v1.0.docx 17.5 KB
2_160603_PreLeisH_Procotol_v2.0.doc 798 KB
3_160603_InformedConsent_part1_v2.0.doc 84.5 KB
4_160603_InformedConsent_part2_v2.0.doc 85 KB
5_Annex_VL-NG.pdf 3.49 MB
6_Annex_FA3.doc 359 KB
7_160608_PreLeisH_1091_-_approval_letter.pdf 79.7 KB
EC_UZA_PreLeisH_initial_approval_161107.pdf 149 KB
Gondar_University_Ethical_clearance_PSP_2017-05-08.pdf 598 KB
ITM_IRB_Amendment_Approval_letter_1091.pdf 52 KB
MSF_ERB_Approval_Amendment_1632_-_16Jan2017.pdf 482 KB
NRERC_Approval_161114.pdf 1.5 MB
PreLeisH_Protocol_v4.0_Amendment_1_signature_Er.pdf 424 KB
MSF_ERB_Amendment_Approval_1632_-_01_Oct_2018.pdf 159 KB
200526_PreLeisH_Procotol_v5.0_clean.pdf 707 KB
20200526_InformedConsent_part1_v4.0_clean.pdf 253 KB
20200618_PreLeisH_CoverLetter_MSF_IRB_Amendment.doc 142 KB
ERB_approval_amendment_1632_13Jul20.pdf 146 KB
200713_PreLeish_InformationLeafletChanges_v2.0_ENG.docx 21.3 KB
MSF_ERB_Review_1632_-_04-Aug-2016.pdf 662 KB
161027_InformedConsent_part1_v3.0_clean.pdf 482 KB
161027_InformedConsent_part1_v3.0_track_changes.pdf 483 KB
161027_InformedConsent_part2_v3.0_clean.pdf 483 KB
161027_PreLeisH_Procotol_v3.0_clean.pdf 885 KB
PreLeisH_Procotol_v3.0_Signature_Johan_20161027.pdf 311 KB
161102_PreLeisH_CoverLetter_MSF_Re-submission2.pdf 110 KB
PreLeisH_Procotol_v3.0_Signature_Lut_20161102.pdf 31.2 KB
PreLeisH_Procotol_v3.0_Signature_Koert_20161031.pdf 60.4 KB
161102_MSF_ERB_Review_1632_Reply_to_comments.docx 33.4 KB
MSF_ERB_Approval_1632_-_09-Nov-2016.pdf 328 KB
MSF_ERB_Approval_Amendment_1632_-_16Jan2017.pdf 482 KB
160630_MSF_Research_Ethics_Review_Template_PreLeish.docx 36.1 KB

Publications

Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study

Johan van Griensven, "–" eBioMedicine "(2024)"
Chronic High-Level Parasitemia in HIV–Infected Individuals With or Without Visceral Leishmaniasis in an Endemic Area in Northwest Ethiopia: Potential Superspreaders?

Johan van Griensven "–" Clinical Infectious Diseases "(2024)"
Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients

Nicky de Vrij "–" Communications Biology "(2024)"
A preliminary indication that HLA-A*03:01 may be associated with visceral leishmaniasis development in people living with HIV in Ethiopia

Nicky de Vrij "–" PLOS Neglected Tropical Diseases "(2024)"

Previous study

Next study